Because ER-positive breast cancers are responsive to circulating estrogens which stimulate breast cancer cell growth, suppression of endogenous estrogen and consequent abrogation of ER-signaling is a critical part of ER-positive breast cancer management. The gene discussed is ESR1; the disease is breast carcinoma.